Gavi pneumonia vaccine pledge wins qualified support from MSF
One of the announcements made by Gavi, The Vaccine Alliance, around Thursday’s Global Vaccine Summit, has been around its donation to the Serum Institute of India.
Gavi will award $75 million of the remaining $262 million of the Advance Market Commitment (AMC) - a $1.5 billion fund that was launched in 2009 to pay for the introduction of the pneumonia vaccine in developing countries - to the Indian manufacturer.
The Serum Institute received quality approval for the pneumonia vaccine in December 2019, joining US drug giant Pfizer (NYSE: PFE) and UK-based GlaxoSmithKline (LSE: GSK), which already had their vaccines at the brink of market entry when the AMC was launched, and have received the bulk of the $1.5 billion subsidy pot, on top of the base price that they charge Gavi.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze